In a phase 2 clinical trial, brostallicin in combination with cisplatin showed promise in treating metastatic triple-negative breast cancer, according to research at the San Antonio Breast Cancer Symposium.
The study evaluated tumors of 47 patients who received cisplatin on the first day, brostallicin on the second day, and GCSF or pegylated-GCSF on the third day, with the cycle repeated every 21 days. About half of the patients had received between two and four prior chemotherapy regimens.
Ten of the patients achieved a confirmed tumor response, nine had a partial response and one had a confirmed response. Fifty-one percent achieved a three-month progression-free survival and 16 percent had a six-month progression-free survival. The median time to progression was 3.2 months.
The study was led by Alvaro Moreno-Aspitia, M.D., assistant professor of medicine at the Mayo Clinic in Jacksonville, Florida. Final results of this trial are expected to be presented at the American Society of Clinical Oncology 2013 Annual Meeting, with a follow-up randomized Phase 2 trial i the works.